Origin Protocol, Inc.

SAN FRANCISCO, CA · Founded 2017 · CIK 0001724266 · Biotech

Multimodal cancer biology datasets from patient tumor tissue including spatial transcriptomics, morphology, proteomics, and perturbation response data

origin.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$38M
3 Form D · Jul 2018
99 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,000,000
Private capital raisedForm D · SEC$28,505,763
Private capital raisedForm D · SEC$6,600,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1913SET THERAPEUTICS INC——
1914Cogent Biosciences——
1915RIPARIAN PHARMACEUTICALS INC—$500K
1916Origin Protocol, Inc.—$38M
1917NGM Bio Holdings, Inc.—$73M
1918CELESTIAL THERAPEUTICS INC—$125K
1919CAMBRIDGE TECHNOLOGIES LLC—$3.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Josh FraserDirector · Executive Officer
  • Matthew LiuDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.